ReviewBioMed research international2025
Applications and Prospects of Single-Cell RNA Sequencing and Spatial Transcriptomics in Cervical Cancer.
Review in BioMed research international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- HIF3A-mediated aberrant activation of TXNIP promotes Alzheimer's disease progression.Scientific reports · 2026Article
- Advancements in single-cell sequencing for cervical cancer research.Molecular and cellular biochemistry · 2026Review
- Exosomes From Adipose-Derived Mesenchymal Stem Cells: A New Prospective Therapy of Diabetic Foot Ulcer.BioMed research international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer (CC) is the fourth commonest malignant tumor among women worldwide and is characterized by high heterogeneity and a complex ecosystem. A comprehensive understanding of the heterogeneity of tumors and the tumor microenvironment (TME) is crucial for effective CC management. Single-cell RNA sequencing (scRNA-seq) is a powerful tool that can be employed to unveil the heterogeneity of tumors and the TME, as well as to elucidate the evolutionary trajectories of tumors. Spatial transcriptomics (ST) technology, on the other hand, can address the complexity and diversity of the spatial microenvironment of tumors, thereby compensating for the limitations of scRNA-seq. As emerging technologies, both scRNA-seq and ST are increasingly being utilized in CC research. In this review, we summarized the latest advancements in scRNA-seq and ST for CC, with a focus on investigating tumor heterogeneity, the TME, tumor evolutionary trajectories, treatment resistance mechanisms, and potential therapeutic targets. These insights collectively contribute to the development of more effective treatment and prevention strategies for CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.